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INTRODUCTION:  Cancer  is  a recognized  risk  factor  of  venous  thromboembolism  (VTE)  as  it induces  a pro-
thrombotic  state  through  various  mechanisms  of  activation  of coagulation.  Recognizing  occult  cancer  as  a
risk  factor  is equally  important.  In  patients  with  no known  thromboembolic  risk factors,  utilizing  PET/CT
as  a screening  tool  may  be considered  in  order  to reveal  occult  malignancy  associated  with  otherwise
unexplainable  VTE.
METHODS:  This  case  report  has  been  reported  in line  with  the  SCARE  criteria.
PRESENTATION  OF CASE:  We  describe  a case  of deep  venous  thrombosis  of  the  lower  leg as the  single  sign
of metastatic  urinary  tract  cancer.  The  patient  had  a  history  of cutaneous  melanoma  but  no thromboem-
bolic  risk  factors.  Following  treatment  for deep  venous  thrombosis,  the  patient  was referred  directly  to
the plastic  surgery  department  for further  examination  including  PET/CT  due  to suspicion  of  metastatic
melanoma.
DISCUSSION:  Screening  for occult  cancer  in  patients  with  unprovoked  VTE  has  so  far  not been  shown  to
beneﬁt  survival.  As new  treatments  emerge,  signiﬁcant  improvement  in  prognosis  might be  expected
with  early  diagnosis  of  occult  cancer  and  initiation  of  treatment.  Thus  an open  mind  should  be kept
towards  utilizing  advanced  diagnostic  tools  such  as PET/CT  to screen  for occult  cancer  in patients  pre-
senting  with  unprovoked  VTE.
CONCLUSION:  This  case  highlights  the importance  of considering  all possible  causes  and utilizing  targeted
diagnostic  tools  when  assessing  a  patient  with  seemingly  unprovoked  deep  venous  thrombosis.  A  whole-
body  PET/CT  scan  ultimately  proved  signiﬁcant  in revealing  occult  metastatic  cancer  of  a completely
different  origin  than  expected.
© 2016  The  Authors.  Published  by Elsevier  Ltd  on  behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
The thromboembolic risk associated with cancer has been
escribed for several speciﬁc malignancies including bladder can-
er [1] and breast cancer [2,3] but only rarely for metastatic
elanoma [4,5], and to our knowledge not for cutaneous
elanoma.
Other known thromboembolic risk factors include immobiliza-
ion, trauma, major surgery, pregnancy, obesity, certain drugs,
dvancing age, some hematological disorders, congenital coagu-
ation factor abnormalities and more.
Both circulating tumor cells and solid tumors may  exhibit pro-
oagulant properties.
∗ Corresponding author at: Department of Plastic Surgery and Breast Surgery,
ealand University Hospital, Sygehusvej 10, 4000 Roskilde, Denmark.
E-mail addresses: jomi@regionsjaelland.dk, joachimm@mschumacher.com
J. Mikkelsen), shm@regionsjaelland.dk (S.H. Matzen).
ttp://dx.doi.org/10.1016/j.ijscr.2016.10.020
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The presence of circulating tumor cells in peripheral blood has
been shown in a prospective study by Mego M et al. [2] to exhibit a
positive association with elevated plasma D-dimer levels in pri-
mary breast cancer, indicating a potential role for activation of
the coagulation cascade by circulating tumor cells. A retrospective
study by Mego M et al. [3] showed a direct association between cir-
culating tumor cells and increased risk of deep venous thrombosis
(DVT) in patients with metastatic breast cancer.
Studies so far have found associations between venous throm-
boembolism (VTE) and certain native properties of cancer cells as
both direct activators of the coagulation cascade, and indirect acti-
vators by stimulating the prothrombotic potential of other cells.
There are several mechanisms involved and considered to be
responsible for a hypercoagulable state in malignancy. It has been
shown that constant expression of Tissue Factor (coagulation factor
III) and Cancer Procoagulant (CP) protein by cancer cells, expression
by cancer cells of ﬁbrinolytic molecules, and cancer cell release of
microparticles and cytokines can induce thrombosis [6,7]. Further-
more direct physical interaction between cancer cells and normal
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
CASE  REPORT  –  OPEN  ACCESS
J. Mikkelsen, S.H. Matzen / International Journal of Surgery Case Reports 28 (2016) 310–313 311
c
a
c
t
i
V
p
b
m
o
2
[
3
m
m
t
d
e
a
p
D
l
<
m
f
p
c
f
w
p
r
l
(
Fig. 2. PET-positive lymph node next to the inferior vena cava.Fig. 1. PET-positive tumors in the liver.
ells has been shown to result in localized clotting activation
nd platelet aggregation, and leukocyte-release of procoagulant
ytokines [8].
We  describe a case from a university hospital, which highlights
he importance of utilizing targeted diagnostic tools when assess-
ng the cause of VTE in a patient with no known risk factors of
TE.
The patient’s history of cutaneous melanoma was  the single
iece of information prompting further examination, and a whole-
ody PET/CT scan ultimately proved vital in revealing an occult
etastatic cancer, which furthermore was of a completely different
rigin than expected.
. Methods
This case report has been reported in line with the SCARE criteria
9].
. Presentation of case
A 78 year old retired, caucasian male was admitted to the
edical emergency department by his general practitioner with
easurable swelling and pain of the left lower leg developed over
he course of a few days prior to admission. He was  on oral Alen-
ronate therapy following a high velocity femur fracture four years
arlier, had a minor use of pipe tobacco, but was otherwise healthy
nd had no family history of thrombosis.
Blood tests and an ultrasound scan of the left lower leg were
erformed, and the patient was subsequently diagnosed with a
VT of the popliteal vein with an elevated Fibrin D-dimer plasma-
evel of 1.06 FEU mg/L (FEU: Fibrin Equivalent Units; normal value:
0.5 FEU mg/L).
Antithrombotic treatment with oral Rivaroxaban was com-
enced and the patient was discharged the day after for routine
ollow-up at the local anticoagulation clinic, and referred to the
lastic surgery department for further examination due to suspi-
ion of metastatic melanoma from cutaneous melanoma treated
our years earlier.
Following examination at the plastic surgery outpatient clinic
here no clinical signs of metastatic melanoma were found, the
atient underwent a whole-body 18F-FDG PET/CT scan, which
evealed several areas suspicious of malignancy in both liver
obes (Fig. 1), in the mediastinal and retroperitoneal lymph nodes
Figs. 2 and 3) and in the long biceps tendon of the right shoulder.Fig. 3. PET-positive lymph nodes surrounding the abdominal aorta.
An ultrasound guided needle biopsy of the liver lesions unex-
pectedly revealed metastatic carcinoma cells of urothelial origin.
Through further diagnostic testing and surgery by the urology
department, the patient was eventually diagnosed with non-
invasive papillary urothelial cancer of the bladder and urothelial
carcinoma located at the right ureter ostium of the bladder.
Four years prior to the DVT the patient was diagnosed with cuta-
neous melanoma on the left leg. Histological examination showed
a superﬁcially spreading melanoma, Clark level 3, Breslow thick-
ness 1.87 millimeters, containing more than one mitosis per square
millimeter in the dermis, and showing signs of regression but no
ulceration.
The melanoma was  treated with wide local excision, and sen-
tinel lymph node biopsy from the left inguinal region revealed no
regional metastases. During the follow-up course the patient was
not diagnosed with further melanoma and never experienced any
general or speciﬁc symptoms of cancer or DVT.
Five months following excision of the melanoma and left-side
inguinal sentinel node biopsy, the patient presented with a pal-
pable mass in the left inguinal region, but had no discomfort or
general symptoms of disease. The mass was removed and revealed
a varicose vein with a thrombus and no signs of malignancy on
histological analysis.
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. Discussion
Venous thromboembolism has been extensively shown to be
ssociated with cancer as well as a signiﬁcantly higher risk of a
ubsequent cancer diagnosis following unprovoked VTE [8,10–12].
Studies so far have found associations between VTE and certain
roperties of cancer cells as both direct activators of the coagulation
ascade, and indirect activators by stimulating the prothrombotic
otential of other cells.
Due to the patient’s history of cutaneous melanoma, metastatic
elanoma was initially considered a possible cause since no other
isk factors for developing DVT were present.
Venous thromboembolism speciﬁcally associated with
elanoma has not been commonly reported in the medical
iterature. Valente M et al. [5] described a case where severe VTE
as associated with pulmonary metastases from a cutaneous
elanoma treated four years earlier. A retrospective study by
parsa A et al. [4] found a high incidence of VTE in metastatic stage
V melanoma with a prevalence comparable to pulmonary and
astrointestinal cancers.
As most cases of melanoma are primarily conﬁned to the super-
cial layers of the skin, the majority of melanomas are as such not in
irect contact with the blood stream as is the case with other malig-
ancies. This might explain the low potential and lack of reported
ases of VTE in cutaneous melanoma.
Two large retrospective population-based cohort studies have
ddressed the likelihood of diagnosing occult cancer following VTE
nd assessed the beneﬁt of cancer screening. A Danish study [10]
ncluding 26,653 patients with unprovoked VTE, and a Taiwanese
tudy [11] published in 2016 including 27,751 patients concluded
hat there was a strong association between unprovoked VTE and
ccult cancer. However, neither study could conclude that exten-
ive screening for occult cancer would beneﬁt survival.
The clinical value of using PET/CT as a standard screening tool
o detect occult cancer in unprovoked DVT, remains a cause of
ebate in regard to improvement in overall survival and morbidity.
 retrospective study [13] published in 2014 including 50 patients
ssessed the value of PET/CT screening for malignancy in patients
ith unprovoked VTE, but showed no diagnostic beneﬁt of PET/CT
ompared to conventional CT scan and concluded that PET/CT had
imited diagnostic value.
Our patient had no known risk factors for VTE by the time he
resented with DVT, but did have a relatively recent history of
elanoma, so there was no hesitation in referring him to a diag-
ostic whole-body 18F-FDG PET/CT scan to examine for melanoma
etastases.
As diagnostic technology evolves and new treatments emerge, a
igniﬁcant improvement in prognosis might be expected with early
iagnosis of occult cancer and initiation of treatment.
Thus an open mind should be kept to future implementation of
outine screening for occult malignancy in patients presenting with
nprovoked VTE, using advanced diagnostic tools such as PET/CT.
. Conclusion
Although the deﬁnitive cause of DVT remained undetermined,
ecognizing occult cancer as a risk factor continues to be important,
specially in patients with no known thromboembolic risk factors,
s demonstrated in this patient.
In the present case, knowledge of previous melanoma was  the
ingle piece of information prompting further examination of the
atient. However, it was a whole-body PET/CT scan utilized as a
argeted diagnostic tool, which ultimately proved vital in revealing
n occult metastatic cancer of a completely different origin than
xpected. This raises the question of whether to implement whole-PEN  ACCESS
f Surgery Case Reports 28 (2016) 310–313
body 18F-FDG PET/CT scan as a standard screening tool to detect
or at least exclude occult malignancy in patients presenting with
otherwise unprovoked DVT.
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